



Vitamin B₁₂ Deficiency in Metformin Treated type 2 Diabetic Patients and Factors Associated with it: A Cross-Sectional Study

Authors

Salunke Arundhati T.¹, Pore Shraddha M.², Ramanand Sunita J.³
Gore Alka D.⁴, Halasawadekar Nimish R.⁵, Jadhav Pradeep G.⁶

^{1,6}Junior Resident, ²Associate Professor, ³Professor & Head of Department, ⁵Assistant Professor
Department of Pharmacology, Government Medical College, Miraj, Dist- Sangli,

Maharashtra- 416410, India

⁴Statistician, Bharti Vidyapeeth Deemed University Medical College, Sangli, Maharashtra-416410, India.

Corresponding Author

Pore Shraddha M.

Department of Pharmacology, Government Medical College, Miraj, Dist-Sangli, Maharashtra- 416410

Phone numbers: 9371126946, Facsimile numbers: 0233-2231958/2231959

Email: shraddha.pore7@gmail.com

Abstract

Objectives: *The objectives of the present study were to assess frequency of vitamin B₁₂ deficiency in metformin treated diabetic patients and to evaluate various factors associated with B₁₂ deficiency.*

Materials and Methods: *This cross-sectional study involved 82 adult patients of type 2 diabetes treated with metformin for at least one year in a tertiary care government hospital. Absolute vitamin B₁₂ deficiency was defined as ≤ 203 pg/ml, values of 203 -298 pg/ml were considered as borderline deficiency and values above >298 pg/ml as normal.*

Results: *The mean age of study population was 60.23 ± 9.20 years. The mean daily dose of metformin was 984.7 ± 185.7 mg. About 41% patients received combination therapy with metformin and glimepiride. Multivitamin supplements were used by 37.8% patients. Absolute vitamin B₁₂ deficiency was found in 7.31% and combined absolute plus borderline deficiency was found 34.1% patients. Age, gender, duration of diabetes, duration of metformin therapy, total daily dose of metformin, HbA1c value, use of sulfonylurea and use of H₂ antihistaminics was not significantly associated with vitamin B₁₂ deficiency. Use of multivitamin led to significant decrease in frequency of vitamin B₁₂ deficiency (16.1% vs. 45.1%, $p=0.007$).*

Conclusion: *Substantial proportion of patients receiving long term metformin show biochemical deficiency of Vitamin B₁₂. Use of multivitamin significantly reduces likelihood of vitamin B₁₂ deficiency.*

Keywords: *metformin, vitamin B₁₂, risk factors.*

Introduction

Type 2 diabetes mellitus (T2DM) is a major health concern in India. Metformin a biguanide, that has been shown to reduce micro-vascular and macro-

vascular complications of T2DM is recommended as an initial pharmacotherapy by current treatment guidelines.^[1] Consequently, metformin is commonly used oral medication in T2DM.

One of the potential adverse effects with long term metformin therapy is vitamin B₁₂ deficiency secondary to reduced absorption from its absorption site in terminal ileum.^[2] Malabsorption of vitamin B₁₂ in 30% of patients receiving metformin on continuous basis was shown in 1971.^[3] Afterwards, first clinical trial of efficacy of metformin by DeFronzo *et al.*, and subsequent long term clinical trials, observational studies and meta-analyses concluded that metformin treatment leads to reduced serum vitamin B₁₂ levels in a dose dependent manner.^[4-8]

Although metformin induced vitamin B₁₂ is generally not associated with overt clinical manifestations, it has been linked to worsened peripheral neuropathy, depression and cognitive impairment in T2DM patients.^[9-11] Early detection and prompt treatment of vitamin B₁₂ deficiency is crucial to prevent irreversible neurological consequences. But unfortunately routine monitoring of serum B₁₂ levels in metformin treated T2DM patients is not practiced uniformly.^[12] Diabetic patients seeking treatment at government hospitals mainly belong to poor socio-economic strata and are even more vulnerable to vitamin B₁₂ deficiency compared to developed countries.^[13]

Based on this background information, we hypothesized that higher proportion of metformin treated T2DM patients in our setting would be suffering from vitamin B₁₂ deficiency. Determining factors associated with vitamin B₁₂ deficiency was also deemed essential. The findings of such study would help to determine the need for vitamin B₁₂ screening and/or prophylactic treatment with vitamin B₁₂ in vulnerable patients.

Materials and Methods

Ethics Statement

The present study was approved by Institutional Ethics Committee. All participants gave their written informed consent.

Study design and participants

This cross-sectional study was conducted in outpatient setting of a tertiary care government teaching hospital. Consecutive sampling was used

to enroll patients during November 2015 to October 2016. Male and female patients of at least 18 years of age diagnosed with T2DM and receiving metformin for more than one year were included in the study. Patients with Type1 DM, pregnant patients, patients suffering from liver, kidney, thyroid disorders, HIV positive patients, alcoholics, those with history suggestive of malabsorption (irritable bowel disease, gastrectomy, ileal resection) and patients declining to participate were excluded from the study.

Data Collection

Information about demographic data, details of medical history, food habits, metformin dose and duration, other antidiabetic and concomitant medications, concomitant illnesses if any, investigations etc. was gathered from patients' medical records and also by enquiring with patients wherever required. This data was then entered into predesigned case record form.

Laboratory investigations

Fasting Sample was used for serum Vitamin B₁₂ and HbA1c estimation. Vitamin B₁₂ was measured by electrochemiluminescence immunoassay method (system: Cobas Elecsys 2010, Roche Diagnostics, Germany) while HbA1c was measured using high performance liquid chromatography (HPLC) method (System – HPLC, BIORAD, USA).

Data Analysis

Proportion of T2DM patients with normal levels of vitamin B₁₂ and those with absolute and borderline deficiency of vitamin B₁₂ was calculated. Absolute vitamin B₁₂ deficiency was defined as ≤ 203 pg/ml, values of 203 -298 pg/ml were considered as borderline deficiency and values above >298 pg/ml as normal, based on cut-off values reported in previous studies.^[6]

Statistical Analysis

For sample size calculation prevalence was considered to be 31%, error (d) and level of significance (α) were fixed at 10% and 5% respectively. This gave sample size of 82 patients.

Data analysis was performed with Statistical Package for Social Sciences (SPSS) version 22.0 U.S.A. The baseline characteristics and study variables are expressed as Mean \pm S.D. or percentages. Association of vitamin B₁₂ with various factors was studied by using chi square test for categorical variables and Mann-Whitney U test for continuous variables. Values of <0.05 were considered statistically significant.

Results

During study period, 220 T2DM patients were screened. The details of sample recruitment is shown in Figure 1. Demographic and baseline data (Table 1) showed that mean age of study population was 60.23 ± 9.20 years. The mean daily dose of metformin was 984.7 ± 185.7 mg. Majority of these (87.8%) patients received 1000 mg metformin daily. About 41.46 % (34/82) patients received combination therapy with metformin and glimepiride. Multivitamin supplements were used by 37.8% (31/82) patients. Vitamin B₁₂ levels were normal in 54 patients (65.9%). Borderline deficiency was seen in 22 (26.82%) patients while absolute deficiency was seen in six (7.31%) patients. Combined borderline and absolute deficiency (≤ 298 pg/ml) was seen in 28 (34.1%) patients (Table 2). As shown in Table 3 and 4, age, gender, duration of diabetes, duration of metformin therapy, total daily dose of metformin, HbA1c value, use of sulfonylurea and use of H₂ antihistaminics was not significantly associated with vitamin B₁₂ deficiency. Use of multivitamin led to significant decrease in frequency of vitamin B₁₂ deficiency (16.1% vs. 45.1%, $p=0.007$).

Discussion

Metformin therapy is an integral part of pharmacological management of T2DM. Association of metformin treatment with reduction in serum vitamin B₁₂ levels is now well established. Given the high prevalence of biochemical and metabolic deficiency of serum vitamin B₁₂ in general Indian population^[14] and paucity of studies in diabetic patients, estimating frequency of vitamin

B₁₂ deficiency and finding variables associated with it in metformin treated T2DM patients in our setting was deemed essential. About 7.31% patients in the present study showed absolute vitamin B₁₂ deficiency while combined absolute and borderline vitamin B₁₂ deficiency was observed in 34.1% of patients. A cross-sectional study by Singh *et al.*,^[15] in Indian patients found definite vitamin B₁₂ deficiency in 7.14% and possible vitamin B₁₂ in 21.4% which supports our findings. Our results are more or less similar to several previous studies.^[16-18]

The prevalence of vitamin B₁₂ deficiency varies widely in literature and thus true prevalence of vitamin B₁₂ deficiency is difficult to estimate. This wide variation is mainly attributable to different cut-off values used to define vitamin B₁₂ deficiency, different laboratory methods used to estimate serum vitamin B₁₂ values, different inclusion and exclusion criteria, variation in mean total daily dose of metformin and total duration of metformin treatment.

The clinical significance of vitamin B₁₂ deficiency in metformin treated diabetic patients is debatable. But several researchers have linked metformin induced vitamin B₁₂ deficiency with serious clinical manifestations such as worsening of peripheral neuropathy, depression and cognitive impairment.^[9-11]

Estimation of serum vitamin B₁₂ levels is most commonly used method for diagnosis of vitamin B₁₂ levels because of relatively low cost. But measurement of serum vitamin B₁₂ may not reliably detect deficiency. Hence measurement of serum homocysteine and/or methylmalonic acid has been recommended to confirm deficiency in asymptomatic high risk patients with low normal levels of vitamin B₁₂.^[19]

The mechanisms underlying metformin induced vitamin B₁₂ deficiency are not exactly known. Changes in small intestinal motility, bacterial overgrowth, consumption of vitamin B₁₂ by bacteria, altered intrinsic factor,^[20] and inhibition of calcium dependent ileal membrane absorption of vitamin B₁₂^[21] have been suggested. An experimental study by Greibe *et al.*, suggest metformin decreases circulating vitamin B₁₂ by

increasing liver accumulation rather than causing malabsorption.^[22] Oral administration of high dose vitamin B₁₂ (1 - 2 mg daily) is as effective as intramuscular administration in correcting the deficiency, regardless of etiology.^[19]

The present study also tried to assess various factors associated with vitamin B₁₂ deficiency. We have evaluated association of age, gender, duration of T2DM, duration of metformin therapy, total daily dose of metformin, HbA1c level, use of H₂ antihistaminics, use of sulfonylurea and use of multivitamin. We found no significant association between vitamin B₁₂ deficiency and age, gender, duration of T2DM, duration of metformin therapy, total daily dose of metformin, HbA1c level, use of H₂ antihistaminics or use of sulfonylurea. But patients taking multivitamin showed significant reduction in combined absolute plus borderline deficiency (16.1% vs. 45.1%, p=0.007). A study by Damio *et al.*, found no association between vitamin B₁₂ deficiency and age, gender, T2DM duration or metformin dose but use of H₂ antihistaminics and metformin duration ≥ 10 years were associated with biochemical vitamin B₁₂ deficiency.^[18]

A study by Aroda *et al.*, did not find association between age, gender or prescription acid suppression use, the only significant predictor of vitamin B₁₂ deficiency in this study was total metformin years of exposure.^[23] Ko *et al.*, found higher dose and long duration of metformin use to be significantly associated with vitamin B₁₂ deficiency but age, gender, HbA1c level, use of H₂ antagonist or sulfonylureas was not associated with vitamin B₁₂ deficiency.^[24]

Singh *et al.*, report significant negative correlation between cumulative metformin dose and duration of metformin treatment.^[15] A study by Nervo *et al.*, showed no association of vitamin B₁₂ levels with gender, HbA1c or dose of metformin but vitamin B₁₂ levels were negatively associated with duration of metformin use and age and positively associated with daily intake of vitamin B₁₂.^[17] A study by Pflipsen *et al.*, showed no association of vitamin B₁₂ deficiency with current or history of metformin use, H₂ antihistaminics use, age etc. In this study

multivitamin use on daily basis lowered prevalence of vitamin B₁₂ deficiency significantly.^[16]

Overall our findings with regard to non-significant association between vitamin B₁₂ deficiency and age, gender, duration of T2DM, HbA1c level, use of H₂ antihistaminics, use of sulfonylurea are supported by previous studies.

One of the important finding of the present study was protective effect of multivitamin against metformin induced vitamin B₁₂ deficiency. The multivitamin preparation in our setting contained 15 micrograms of vitamin B₁₂. Similar protective effect of multivitamin or vitamin B₁₂ supplements is reported by several previous studies.^[6,16,17,25]

Several researchers have reported dose and duration of metformin therapy as an important predictor of vitamin B₁₂ deficiency.^[7,9,15,18,22,23,24,26] But present study could not find significant association between total daily metformin dose or duration of metformin therapy with vitamin B₁₂ deficiency. The reason for this could be the mean daily dose of metformin in our study population was only 984.7mg/day and majority (87.8%) patient received 1000 mg/day which is far lower than maximum recommended dose of 2550 mg.^[2] A systematic review by Liu *et al.*, based on six randomized controlled trials found metformin dose >2000 mg was significantly associated with metformin induced reduction in serum vitamin B₁₂ levels.^[7] Likewise study by Akinlade *et al.*, also showed metformin dose of >1000 mg to be significantly associated with vitamin B₁₂ levels.^[27]

There are some limitations to our study. First, we did not measure homocysteine or methylmalonic acid to confirm metabolic deficiency of vitamin B₁₂ as these laboratory investigations are not routinely performed in our setting. Second, being cross-sectional study, we could only describe association between various factors and vitamin B₁₂ deficiency but cannot prove causality. Third, this study involved small number of patients from a single tertiary care government hospital catering mainly to patients from low socioeconomic status and where oral hypoglycaemic treatment was confined to use of metformin and glimepiride. Therefore results of

this study may not be applicable to patients receiving treatment with large number of recently introduced drugs or different therapeutic regimens and belonging to higher socioeconomic strata.

Conclusions

In conclusion, absolute vitamin B₁₂ deficiency was found in 7.31% and combined absolute plus borderline deficiency was found 34.1% of T2DM patients receiving mean metformin dose of 984.7 mg/day for more than a year. Use of multivitamin significantly reduced likelihood of vitamin B₁₂ deficiency thus supporting its use in high risk patients receiving metformin. Further large scale longitudinal studies incorporating metabolic markers of vitamin B₁₂ deficiency would be needed to clarify the role of early detection of metformin induced vitamin B₁₂ deficiency and its impact on clinical manifestations.

References

1. American Diabetes Association. Standards of medical care in diabetes-2016. *Diabetes Care* 2016;39:S1-S109.
2. Powers AC, D'Alessio. Endocrine Pancreas and Pharmacotherapy of Diabetes Mellitus and Hypoglycemia. In, Brunton LL (ed). Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th edition. United States, The McGraw-Hill Companies, 2011;1258-59.
3. Tomkin GH, Hadden DR, Weaver JA, Montgomery DA. Vitamin-B₁₂ status of patients on long-term metformin therapy. *Br Med J* 1971;2:685-7.
4. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with noninsulin-dependent diabetes mellitus. *N Engl J Med* 1995;333:541-9.
5. DeJager J, Kooy A, Lehert P, Wulffele MG, van der Kolk J, Bets D, *et al.* Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B₁₂ deficiency: randomised placebo controlled trial. *BMJ* 2010;340:c2181.
6. Reinstatler L, Qi YP, Williamson RS, Garn JV, Oakley Jr GP. Association of biochemical B₁₂ deficiency with metformin therapy and vitamin B₁₂ supplements: the National Health and Nutrition Examination Survey, 1999–2006. *Diabetes Care* 2012;35:327–33.
7. Liu Q, Li S, Quan H, Li J. Vitamin B₁₂ status in metformin treated patients: systematic review. *PLoS One* 2014;9:e100379.
8. Niafar M, Hai F, Porhomayon J, Nader ND. The role of metformin on vitamin B₁₂ deficiency: a metaanalysis review. *Intern Emerg Med* 2015;10:93-102.
9. Wile DJ, Toth C. Association of Metformin, Elevated Homocysteine, and Methylmalonic Acid Levels and Clinically Worsened Diabetic Peripheral Neuropathy. *Diabetes Care* 2010;33:156-161.
10. Moore EM, Mander AG, Ames D, Kotowicz MA, Carne RP, Brodaty H, *et al*; AIBL Investigators. Increased risk of cognitive impairment in patients with diabetes is associated with metformin. *Diabetes Care* 2013;36:2981.
11. Biemans E, Hart HE, Rutten GE, Cuellar Renteria VG, Kooijman-Buiting AM, Beulens JW. Cobalamin status and its relation with depression, cognition and neuropathy in patients with type 2 diabetes mellitus using metformin. *Acta Diabetol* 2015;52:383-93.
12. Pierce SA, Chung AH, Black KK. Evaluation of vitamin B₁₂ monitoring in a veteran population on long-term, high-dose metformin therapy. *Ann Pharmacother* 2012;46:1470-6.
13. Allen LH. How common is vitamin B₁₂ deficiency? *Am J Clin Nutr* 2009;89:693S–6S.
14. Refsum H, Yajnik CS, Gadkari M, Schneede J, Vollset SE, Orning L, *et al.* Hyperhomocysteinemia and elevated methylmalonic acid indicate a high

- prevalence of cobalamin deficiency in Asian Indians¹⁻³. *Am J Clin Nutr* 2001;74:233–41.
15. Singh AK, Kumar A, Karmakar D, Jha RK. Association of B₁₂ deficiency and clinical neuropathy with metformin use in type 2 diabetes patients. *J Postgrad Med* 2013;59:253–7.
 16. Pflipsen MC, Oh RC, Saguil A, Seehusen DA, Topolski R. The prevalence of vitamin B₁₂ deficiency in patients with type 2 diabetes: a cross-sectional study. *J Am Board Fam Med* 2009; 22:528-34.
 17. Nervo M, Lubini A, Raimundo FV, Faulhaber GA, Leite C, Fischer LM, *et al*. Vitamin B₁₂ in metformin-treated diabetic patients: a cross sectional study in Brazil. *Rev Assoc Med Bras* 2011;57:46–49.
 18. Damião CP, Rodrigues AO, Pinheiro MF, Cruz Filho RA, Cardoso GP, Taboada GF, *et al*. Prevalence of vitamin B₁₂ deficiency in type 2 diabetic patients using metformin: a cross-sectional study. *Sao Paulo Medical Journal* 2016;134:473-9.
 19. Langan RC, Zawistoski KJ. Update on Vitamin B₁₂ Deficiency. *American family physician* 2011;83: 1425-1430.
 20. 2Andrès E, Noel E, Goichot B. Metformin-associated vitamin B₁₂deficiency. *Arch Intern Med* 2002;162:2251-2.
 21. Bauman WA, Shaw S, Javatileke F, Spungen AM, Herbert V. Increased intake of calcium reverses vitamin B₁₂ malabsorption induced by metformin. *Diabetes Care* 2000;23:1227–31.
 22. Greibe E, Trolle B, Bor MV, Lauszus FF, Nexø E. Metformin lowers serum cobalamin without changing other markers of cobalamin status: A study on women with polycystic ovary syndrome. *Nutrients* 2013;5:2475-2482.
 23. Aroda VR, Edelstein SL, Goldberg RB, Knowler WC, Marcovina SM, Orchard TJ, *et al*; Diabetes Prevention Program Research Group. Long-term Metformin Use and Vitamin B₁₂ Deficiency in the Diabetes Prevention Program Outcomes Study. *J Clin Endocrinol Metab* 2016 ;101:1754-61.
 24. Ko SH, Ko SH, Ahn YB, Song KH, Han KD, Park MY, *et al*. Association of Vitamin B₁₂ Deficiency and Metformin Use in Patients with Type 2 Diabetes. *JKMS* 2014;29:965-72.
 25. Kancherla V, Garn JV, Zakai NA, Williamson RS, Cashion WT, Odewole O, *et al*. Multivitamin Use and Serum Vitamin B₁₂Concentrations in Older-Adult Metformin Users in REGARDS, 2003-2007. *PLoS One* 2016;11:e0160802.
 26. Beulens JW, Hart HE, Kuijs R, Kooijman-Buiting AM, Rutten GE. Influence of duration and dose of metformin on cobalamin deficiency in type 2 diabetes patients using metformin. *Acta Diabetol* 2015;52:47-53.
 27. Akinlade KS, Agbebaku SO, Rahamon SK, Balogun WO. Vitamin B₁₂ levels in patients with type 2 diabetes mellitus on metformin. *Annals of Ibadan Postgraduate Medicine* 2015;13:79-83.